Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T0001 PK and Tolerance in Healthy Volunteers
NCT02291471Phase 1Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Oct 2014
- Primary completion
- Feb 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Hitanercept in rheumatoid arthritis (RA), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoint: Maximum Tolerance Dose at 3 weeks. Started Oct 2014; status: completed.
02
Drugs
Hitanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02291471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291471.